EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

Sofia Attelind iD, Niclas Eriksson iD, Marco Cavalli iD, Yiyi Xu iD, Fredrik Nyberg iD, Anders Sundström iD, Mia Wadelius iD, Pär Hallberg iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70614 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Sofia Attelind und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Clinical Pharmacogenomics, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Registries, Venous Thromboembolism. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Brain Foundation, Swedish Heart-Lung Foundation, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines.

Methods

We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish Medical Products Agency. Two hundred one cases (43% women, 91% Swedish) were compared with 4891 Swedish population controls. Analyses were performed on two candidate variants in coagulation factor II (rs1799963) and coagulation factor V (rs6025), on 14 prespecified candidate genes and across the whole genome. To support the findings, we conducted an observational register study of the Swedish general population with/without a diagnosis of thrombophilia and the risks of venous thromboembolism after SARS‐CoV‐2 vaccination.

Results

In the GWAS, the main findings were that the candidate variants of coagulation factors II rs1799963 and V rs6025 were significantly associated with venous thromboembolism (odds ratio [OR] 2.4 [95% confidence interval (CI) 1.2–4.8], p = .015 and OR 1.8 [95% CI 1.3–2.6], p = .0022). No genetic marker passed the significance threshold in the candidate gene analysis or the full genome‐wide analysis. In the register study, people with a thrombophilia diagnosis had a five‐fold elevated risk of venous thromboembolism within 42 days after vaccination, adjusted for potential confounders, OR 5.06 [95% CI 3.98–6.44].

Conclusion

Well‐characterized genetic variants in the genes of coagulation factors II and V were associated with thromboembolism after SARS‐CoV‐2 immunization. Further research is recommended to elucidate their potential role in vaccine‐related thromboembolic events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesRegistriesVenous ThromboembolismAdultAgedFemaleHumansMaleMiddle AgedCase-Control StudiesFactor VGenetic Predisposition to DiseaseGenome-Wide Association StudyPolymorphism, Single NucleotideProthrombinRisk FactorsSARS-CoV-2SwedenVaccination

Stichwörter der Autor:innen

Covid‐19 vaccinesdrug‐related side effects and adverse reactionsgenome‐wide association studypharmacovigilancevenous thromboembolism

Substanzen

COVID-19 VaccinesFactor VProthrombin

Autor:innen und Institutionen

  • Department of Medical Sciences, Clinical Pharmacogenomics, Uppsala University, Uppsala, Sweden.
  • Department of Drug Safety, Swedish Medical Products Agency, Uppsala, Sweden.
  • Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden.
  • Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg

Förderung

  • Swedish Brain Foundation
  • Swedish Heart-Lung Foundation
  • Swedish Research Council
  • Swedish Stroke Association
  • SciLifeLab/Knut and Alice Wallenberg Foundation
  • Selander's Foundation
  • Clinical Research Support at Uppsala University Hospital (ALF)
  • Uppsala University

Zitieren

APA

Attelind, S., Eriksson, N., Cavalli, M., Xu, Y., Nyberg, F., Sundström, A., Wadelius, M., & Hallberg, P. (2026). Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70614

Vancouver

Attelind S, Eriksson N, Cavalli M, Xu Y, Nyberg F, Sundström A, et al. Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70614

BibTeX
@article{Attelind2026,
  author = {Attelind, Sofia and Eriksson, Niclas and Cavalli, Marco and Xu, Yiyi and Nyberg, Fredrik and Sundström, Anders and Wadelius, Mia and Hallberg, Pär},
  title = {Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70614}
}
Kostenlos starten →